HOOKIPA Pharma Inc

HOOKIPA Pharma Inc(HOOK)股票分析

$0.840

-0.058 (-6.92%)收盤時

Loading chart…
High
0.920
Open
0.903
VWAP
0.87
Vol
589.35K
Mkt Cap
64.33M
Low
0.840
Amount
510.89K
EV/EBITDA, TTM
0.42

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.

估值指標

The current forward P/E ratio for HOOKIPA Pharma Inc (HOOK) is -0.68, compared to its 5-year average forward P/E of -1.16.

Forward P/E

Fair
5Y Average P/E
-1.16
Current P/E
-0.68
高估
-0.55
低估
-1.78

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.20
Current EV/EBITDA
0.42
高估
0.76
低估
-1.16

Forward P/S

Fair
5Y Average P/S
6.02
Current P/S
1.34
高估
10.77
低估
1.27

Alphio AI Price Scenarios for HOOK

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HOOK

$0.61

情境價格

B

Base

Base · 50%HOOK

$0.52

情境價格

B

Bear

Bear · 25%HOOK

$0.42

情境價格

事件時間軸

2026-02-03 (ET)

08:40:00

HOOKIPA Pharma Sells Immuno-Oncology Assets to NeoTrail

2025-12-11 (ET)

06:10:00

Hooker Furnishings Reports Q3 Revenue of $70.7M, Implements New Share Repurchase Plan

06:10:00

Hooker Approves Share Repurchase Program Up to $5 Million

2025-10-31 (ET)

08:05:37

Hookipa Pharma Finalizes Sale of HBV and HIV Assets to Gilead

2025-07-18 (ET)

22:21:58

Hookipa Pharma to delist shares from Nasdaq

資訊

HOOK FAQ — answered by Alphio AI

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始